Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2003, for IDEC Pharmaceuticals Corporation. The company is engaged in the research, development, manufacture, and commercialization of targeted therapies for cancer and autoimmune diseases. Its primary revenue sources are the copromotion of Rituxan (with Genentech) and the direct sales of Zevalin in the United States. A material event during this period is the proposed merger with Biogen, Inc., announced in June 2003, under which IDEC is the acquirer. Stockholder approval for the merger is scheduled for November 12, 2003.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2003 | Nine Months Ended Sep 30, 2003 | Nine Months Ended Sep 30, 2002 |
|---|---|---|---|
| Total Revenues | $138,530 | $379,337 | $280,570 |
| Net Income | $45,500 | $115,466 | $103,496 |
| Diluted EPS | $0.26 | $0.67 | $0.60 |
| Operating Cash Flow (9mo) | N/A | $192,759 | $113,220 |
| Cash & Equivalents (Sep 30, 2003) | $363,678 | N/A | N/A |
| Total Debt (Notes Payable) | $881,956 | N/A | N/A |
Revenue Composition (9 months 2003): Revenues from unconsolidated joint business (Rituxan) totaled $363.2 million (96% of total). Product sales (Zevalin) were $15.1 million. Corporate partner revenues were $1.0 million.
Liquidity: As of September 30, 2003, the company held $1.5 billion in cash, cash equivalents, and securities available-for-sale. Long-term debt consists of subordinated notes due 2019 and senior notes due 2032.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 35% for the nine months ended September 30, 2003, compared to the prior year. This was driven primarily by a 35% increase in revenues from the unconsolidated joint business (Rituxan), attributed to increased market penetration and price increases.
- Product Sales: Net product sales (Zevalin) increased 83% year-over-year for the nine-month period ($15.1M vs $8.3M). However, cost of sales as a percentage of product sales rose to 35% (from 14% in 2002) due to a $3.1 million write-down of Zevalin inventory that did not meet quality specifications.
- Operating Expenses: Research and development (R&D) expenses increased significantly to $113.1 million (from $67.6 million), driven by a $20.0 million payment to Genentech for an amended collaboration agreement and increased personnel and manufacturing costs. Selling, general, and administrative (SG&A) expenses rose to $83.2 million (from $65.9 million) due to legal fees, insurance, and merger-related integration costs.
- Profitability: Net income increased 12% to $115.5 million for the nine-month period, despite higher operating expenses, due to the substantial growth in Rituxan-related revenues.
Guidance, Outlook, Risks, and Unusual Items
- Merger with Biogen: The company is proceeding with a merger to form "Biogen Idec Inc." IDEC stockholders will own approximately 50.5% of the combined entity. A termination fee of up to $230 million may be payable if the merger is terminated under certain circumstances. $5.1 million in merger-related costs have been capitalized to date.
- Legal Proceedings: On October 15, 2003, a federal court granted summary judgment in IDEC's favor in a patent infringement suit regarding Zevalin, ruling the opposing patents unenforceable due to inequitable conduct. The plaintiff (Corixa) expects to appeal. A class-action suit regarding the Biogen merger terms has reached an agreement in principle for resolution.
- Regulatory Risks: Zevalin marketing approval in Europe is pending. The company faces potential reimbursement risks from the Centers for Medicare & Medicaid Services (CMS) regarding payment rates for Zevalin and Rituxan, which could impact commercial success.
- Capital Projects: The company is investing heavily in a new administrative campus ($178 million estimated) and a large-scale manufacturing facility in Oceanside, CA ($400 million estimated). As of September 30, 2003, approximately $240.7 million had been invested in the manufacturing facility.
- Supply Chain: The company relies on a single supplier (MDS Canada) for the yttrium-90 radioisotope required for Zevalin. An escrow fund of $25.0 million has been established to secure this supply.
Investor Verification Checklist
- Merger Approval: Confirm the outcome of the stockholder vote scheduled for November 12, 2003, and the final terms of the Biogen merger.
- Patent Litigation Status: Monitor the appeal of the summary judgment ruling in the Zevalin patent case against Corixa/Glaxo.
- Reimbursement Rates: Verify the final CMS rules for 2004 regarding Zevalin and Rituxan payment rates and their potential impact on margins.
- European Approval: Track the status of Zevalin marketing authorization in the European Union.
- Inventory Quality: Assess the impact of the $3.1 million Zevalin inventory write-down on future cost of sales and production capabilities.